tumor
microenviron
complex
cancer
stem
cell
csc
member
within
commun
popul
possess
capac
selfrenew
caus
cellular
heterogen
tumor
csc
resist
convent
antiprolif
drug
order
cur
imper
csc
must
elimin
cancer
therapi
varieti
dietari
phytochem
reposit
drug
act
synergist
convent
anticanc
agent
review
advoc
develop
novel
approach
name
combin
therapi
incorpor
phytochem
reposit
drug
target
csc
cover
select
dietari
phytochem
curcumin
resveratrol
egcg
genistein
repurpos
drug
metformin
niclosamid
thioridazin
chloroquin
five
eight
curcumin
resveratrol
egcg
genistein
metformin
list
halifax
project
explor
concept
lowtox
broadspectrum
therapeut
approach
could
simultan
target
mani
key
pathway
mechan
compound
discuss
mechan
action
model
anticsc
activ
identifi
well
advantag
challeng
potenti
combin
therapi
cours
lifespan
somat
cell
undergo
chang
genom
epigenom
due
intrins
celldevelopment
extrins
environment
factor
accumul
chang
disrupt
regul
cell
growth
death
result
unchart
growth
lead
cancer
carcinogenesi
multistep
process
initi
promot
progress
metastasi
hallmark
cancer
denot
alter
cancer
cell
physiolog
inde
limit
number
gene
cover
dozen
signal
pathway
process
cell
fate
cell
surviv
genom
mainten
relev
design
driver
mutat
histolog
tumor
heterogen
consist
cancer
cell
variou
stage
differenti
well
cell
type
fibroblast
immun
cell
endotheli
cell
cell
behav
member
commun
tumor
microenviron
nich
complex
interact
network
cancer
stem
cell
csc
cell
within
tumor
possess
dual
capac
selfrenew
caus
heterogen
lineag
cancer
cell
compris
tumor
convent
chemotherapi
target
bulk
prolifer
cancer
cell
exampl
paclitaxel
sever
cancer
type
imatinib
tyrosin
kinas
inhibitor
chronic
myelogen
leukemia
cml
howev
csc
resist
anticanc
drug
cur
cancer
therapi
must
acknowledg
csc
plastic
complet
elimin
mani
csctarget
dietari
phytochem
act
synergist
convent
anticanc
agent
recent
investig
discov
csctarget
repurpos
drug
advoc
novel
approach
combin
therapi
pair
csctarget
phytochem
reposit
drug
interest
ovarian
cancer
led
us
phytochemicaldrug
combin
anticanc
studi
demonstr
benefit
specif
phytochem
combin
individu
compound
dietari
phytochem
reposit
drug
provid
easier
access
toward
clinic
use
former
gener
regard
safe
gra
statu
latter
prior
food
drug
administr
fda
approv
innov
approach
advantag
compound
target
csc
activ
insurmount
current
anticanc
agent
csc
target
recommend
four
dietari
phytochem
curcumin
resveratrol
egcg
genistein
four
repurpos
drug
metformin
niclosamid
thioridazin
chloroquin
see
fig
applic
csctarget
phytochemicaldrug
combin
furthermor
five
curcumin
resveratrol
egcg
genistein
metformin
list
intern
task
forc
clinician
scientist
halifax
project
dedic
object
explor
concept
lowtox
broadspectrum
therapeut
approach
could
simultan
target
mani
key
pathway
mechan
cancer
treatment
block
et
al
state
among
approach
curcumin
genistein
resveratrol
egcg
boast
wealth
fundament
research
awar
investig
may
disagre
select
phytochem
other
also
cite
eight
efficaci
low
cost
free
intellectu
properti
constraint
attribut
make
sure
combin
wide
afford
econom
compar
current
chemoand
target
therapi
differ
convent
anticanc
drug
uniqu
molecular
target
dietari
phytochem
repurpos
drug
pleiotrop
multitud
cellular
target
shown
later
compound
descript
multilater
target
molecular
cellular
pathway
inhibit
csc
growth
induc
csc
differenti
hinder
csc
abil
develop
resist
case
promiscu
drug
virtu
dirti
might
better
phytochemicaldrug
combin
advantag
synergist
effect
pair
allow
lower
effect
dose
use
singl
compound
activ
lower
dose
mean
less
potenti
toxic
fewer
side
effect
particular
cancer
variou
combin
explor
look
ideal
pair
optim
dose
clinic
use
combin
use
alon
csc
bulk
cancer
cell
elimin
adjuv
convent
cancer
therapi
combin
target
csc
convent
therapi
elimin
bulk
cancer
cell
approach
csctarget
dietari
phytochemicalreposit
drug
combin
import
reason
present
comprehens
pictur
start
consider
csc
methodolog
variou
observ
made
evolv
concept
csc
follow
compound
descript
end
challeng
need
appli
csctarget
phytochemicaldrug
combin
current
climat
cancer
therapi
human
csc
first
discov
leukemia
character
solid
tumor
util
array
mechan
csc
insensit
convent
cancer
treatment
mechan
target
phytochem
drug
describ
later
see
fig
key
mechan
csc
resist
therapi
csc
may
quiescent
exhibit
slow
prolifer
natur
may
possess
effici
dna
repair
system
activ
genom
instabl
regul
epigenet
modif
via
histon
deacetylas
prosurviv
signal
pathway
may
activ
hedgehog
wnt
notch
csc
may
high
level
antiapoptot
molecul
drug
resist
activ
drug
transport
high
level
express
atpbind
cassett
abc
membran
transport
drug
efflux
enzym
aldehyd
dehydrogenas
aldh
drug
metabol
activ
detect
addit
nich
less
reactiv
oxygen
speci
ro
thu
less
suscept
radiat
therapi
one
notabl
cscassoci
featur
epithelialmesenchym
transit
emt
process
epitheli
cell
lose
polar
becom
less
adhes
chang
cell
becom
invas
migratori
mesenchymallik
stem
properti
process
involv
activ
transcript
factor
snail
twist
chang
marker
protein
eto
ncadherin
first
seen
embryogenesi
emt
view
reappear
embryon
featur
cancer
cell
process
revers
link
csc
tumor
heterogen
metastasi
emt
involv
csc
activ
research
csc
identifi
vitro
vivo
method
isol
via
fluorescenceactiv
cell
sort
fac
surfac
antigen
detoxif
capac
csc
express
identifi
cell
surfac
antigen
exampl
ovarian
csc
express
molecul
serv
biomark
allow
isol
fac
aldh
detoxif
enzym
oxid
aldehyd
carboxyl
acid
metabol
excret
via
liver
activ
util
csc
select
fac
use
fluoresc
substrat
aldefluor
side
popul
sp
assay
identifi
csc
apart
main
popul
cancer
cell
flow
cytometri
fast
expuls
fluoresc
dye
hoechst
howev
cell
surfac
marker
csc
select
also
present
normal
stem
cell
cell
type
uniqu
csc
sp
aldh
select
origin
develop
hematopoiet
stem
cell
hsc
adapt
csc
spheroid
cultur
anoth
method
identifi
csc
cancer
cell
transform
due
mutat
exhibit
anchorag
independ
characterist
allow
form
cell
coloni
absenc
substratum
shown
soft
agar
coloni
format
assay
normal
cell
die
absenc
attach
via
process
anoiki
serumfre
spheroid
cultur
sphere
cancer
cell
grow
spheroid
suspens
untreat
plastic
ware
provid
specif
growth
factor
insulin
epiderm
growth
factor
basic
fibroblast
growth
factor
unlik
ordinari
tissu
cultur
cell
usual
grow
monolay
fetal
bovin
serum
growth
factor
compon
spheroid
mimic
threedimension
natur
tumor
limit
oxygen
avail
intern
cell
hypox
condit
favor
express
pluripot
maintain
transcript
factor
thu
promot
differenti
csc
facilit
state
stem
spheroid
form
secondari
tertiari
sphere
subsequ
cultur
csc
known
neoplast
sphereform
cell
measur
enumer
secondari
sphere
gener
replat
sphere
base
assumpt
secondari
sphere
clone
techniqu
spheroid
cultur
origin
develop
neurobiolog
adapt
csc
apart
vitro
method
gold
standard
csc
neoplasiainiti
cell
regener
detect
neoplast
popul
xenograft
immunodefici
mice
vivo
csc
isol
either
fresh
tumor
establish
cell
line
transplant
initi
tumor
growth
immunocompromis
recipi
anim
differ
model
avail
athym
nude
mice
nonobes
diabet
sever
combin
immunodefici
nodscid
mice
nodscid
receptor
gamma
chain
null
nsg
mice
abund
csc
tumor
sampl
estim
xenotransplant
yield
confirm
presenc
csc
limit
dilut
analysi
mani
compound
natur
naturalderiv
synthet
report
csctarget
two
strategi
avail
compound
identif
pathwayspecif
approach
gener
high
throughput
mass
screen
approach
first
yield
cyclopamin
plant
corn
lili
veratrum
californicum
target
glioblastoma
csc
via
hedgehog
pathway
act
teratogen
caus
cyclopia
second
yield
salinomycin
bacterium
streptomyc
albu
toxic
human
use
confin
poultri
industri
coccidiostat
treat
parasit
protozoan
diseas
clinic
use
medicin
chemist
must
modifi
remov
teratogen
toxic
identifi
compound
must
target
csc
normal
stem
cell
even
though
csc
differ
bulk
cancer
cell
may
share
gene
express
signal
pathway
normal
stem
cell
csctarget
phytochem
drug
discuss
follow
section
dietari
phytochem
advantag
compound
usual
low
toxic
contrast
chemotherapeut
drug
present
commonli
consum
food
readili
avail
peopl
daili
life
shown
potenti
adjuv
chemotherapi
origin
studi
cancer
chemoprevent
initi
chemoprevent
growth
cancer
chemotherapi
may
share
common
molecular
mechan
appli
cancer
therapi
furthermor
phytochem
overcom
drug
resist
ovarian
cancer
act
gene
noncod
gene
regulatori
pathway
microrna
importantli
phytochem
target
csc
comment
csc
dietari
phytochem
kim
et
al
wrote
dietinduc
shift
deregul
regul
cancer
stem
cell
could
profound
influenc
cancer
relaps
therefor
immens
societ
import
instead
diet
propos
use
csctarget
phytochemicaldrug
combin
cancer
therapi
laboratori
studi
phytochem
curcumin
quercetin
egcg
polyphenol
act
synergist
cisplatin
convent
anticanc
drug
growth
inhibit
drugresist
ovarian
cancer
cell
line
compound
activ
csc
vitro
well
cancer
diseas
anim
model
clinic
trial
though
date
none
approv
cancer
treatment
discuss
four
csctarget
phytochem
curcumin
resveratrol
egcg
genistein
see
tabl
select
cancer
clinic
trial
four
phytochem
http
clinicaltrialsgov
curcumin
diferuloylmethan
biolog
principl
indian
spice
turmer
give
curri
powder
yellow
color
turmer
produc
rhizom
plant
curcuma
longa
multipl
util
health
benefit
tradit
indian
medicin
insect
bite
wound
heal
wide
studi
properti
curcumin
antiinflamm
curcumin
inhibit
mani
proinflammatori
gene
product
includ
enzym
induc
nitric
oxid
synthas
ino
transcript
factor
nuclear
factor
kappa
b
cytokin
tumor
necrosi
factor
chemokin
use
lipopolysaccharid
lp
induc
murin
sepsi
model
report
curcumin
ingest
gavag
downregul
ino
gene
express
murin
liver
curcumin
may
suppress
carcinogenesi
downregul
inflamm
support
cancer
cell
surviv
prolifer
invas
anoth
wide
studi
anticanc
properti
curcumin
csctarget
see
tabl
select
cellular
target
phytochem
drug
csc
csc
resist
convent
anticanc
drug
suscept
curcumin
curcumin
act
stem
cell
signal
pathway
implic
process
carcinogenesi
includ
wnt
notch
hedgehog
signal
transduct
activ
stat
exampl
hepatocellular
carcinoma
csc
tsai
et
al
report
curcumin
inhibit
sp
invas
emt
reduc
tumor
size
lung
metastasi
nude
mice
xenograft
model
immunoblot
reveal
sphingosin
receptor
signal
pathway
inhibit
cell
cultur
subramaniam
et
al
report
curcumininduc
apoptosi
esophag
cancer
cell
decreas
esophag
csc
spheroid
size
number
molecular
mechan
inhibit
notch
pathway
seen
decreas
rna
protein
express
secretas
protein
ligand
investig
also
found
downregul
oncomir
mirna
upregul
tumor
suppressor
mirna
mirna
curcumintr
esophag
csc
spheroid
similar
esophag
exampl
colorect
csc
ramasami
et
al
report
curcumininduc
epigenet
modif
includ
methyl
epiderm
growth
factor
receptor
egfr
promot
express
microrna
oncomir
relev
metastasi
emt
well
suppress
csc
marker
aldh
thu
curcumin
modifi
epigenet
induc
specif
methyl
chang
regul
microrna
express
huminiecki
et
al
review
function
genom
studi
curcumin
microarray
methyl
array
microrna
array
rnaseq
conclud
curcumin
power
effect
gene
express
includ
gene
involv
cell
signal
apoptosi
control
cell
cycl
curcumin
induc
csc
differenti
zhuang
et
al
report
curcumin
promot
differenti
glioma
csc
induc
autophagi
use
immunofluoresc
show
decreas
stem
marker
increas
differenti
marker
tubulin
curcumin
alter
chemosensit
synerg
convent
drug
specif
csc
vitro
curcumin
enhanc
cisplatin
effect
nonsmal
cell
lung
csc
found
curcumin
daili
day
via
medium
chang
reduc
sp
rat
glioma
cell
possibl
via
inhibit
drug
transport
vivo
curcumin
enhanc
paclitaxel
effect
brain
tumor
csc
sensit
breast
csc
mitomycin
c
nude
mice
xenograft
model
sever
reason
propos
explain
cscspecif
action
low
advers
toward
normal
stem
cell
curcumin
uptak
may
greater
csc
curcumin
may
target
csc
microenviron
obvious
differ
normal
stem
cell
exampl
buhrmann
et
al
report
curcumin
sensit
colorect
csc
toward
fluorouracil
suppress
crosstalk
csc
stromal
fibroblast
tumor
nich
use
cocultur
assay
emt
marker
immunoblot
resveratrol
stilben
grape
peanut
pine
nut
present
red
white
wine
associ
skin
grape
pleiotrop
agent
multipl
cellular
target
exampl
inhibit
mammalian
target
rapamycin
mtor
pathway
cyclooxygenas
cox
enzym
play
role
inflammatori
diseas
diabet
obes
cardiovascular
diseas
neurolog
disord
cancer
resveratrol
also
activ
ampactiv
protein
kinas
ampk
key
nutrient
sensor
sirtuin
deacetylas
lead
lifespan
extens
yeast
nematod
fruit
fli
fish
obes
mice
normal
mice
retard
age
process
mammal
similar
calor
restrict
furthermor
resveratrol
phytoalexin
compound
produc
plant
pathogen
fungal
infect
grape
plant
found
properti
har
inhibit
growth
human
cutan
fungal
speci
thu
potenti
use
tinea
ringworm
athlet
foot
cancer
resveratrol
target
csc
park
pezzuto
review
molecular
alter
result
resveratrol
intervent
differ
breast
prostat
lung
colorect
cancer
model
gener
approach
studi
isol
csc
assay
effect
resveratrol
vitro
vivo
compar
csc
bulk
cancer
cell
determin
molecular
mechan
modul
exampl
fu
et
al
report
resveratrol
cytotox
breast
csc
vitro
mechanist
immunofluoresc
immunoblot
microtubuleassoci
protein
light
chain
catenin
protein
show
induc
autophagi
suppress
wnt
pathway
resveratrol
also
inhibit
spheroid
format
decreas
aldh
cell
decreas
tumor
size
murin
xenograft
shankar
et
al
report
resveratrol
inhibit
pancreat
csc
spheroid
format
via
induct
apoptosi
inhibit
mrna
express
pluripot
mainten
transcript
factor
oct
nanog
well
interfer
emt
similar
inhibit
also
observ
transgen
mous
model
pancreat
ductal
adenocarcinoma
glioblastoma
multiform
found
csc
pretreat
resveratrol
vitro
less
tumorigen
xenograft
scid
mice
surviv
better
untreat
counterpart
investig
also
perform
microarray
analys
shrna
confirm
compar
effect
resveratrol
csc
noncsc
resveratrol
inhibit
stem
gene
express
induc
csc
differenti
via
suppress
pathway
resveratrol
like
curcumin
cscspecif
spare
normal
stem
cell
pandey
et
al
report
resveratrol
block
gene
express
fatti
acid
synthas
inhibit
breast
csc
growth
enzym
normal
human
mammari
epitheli
cell
suscept
fu
et
al
report
resveratrol
cytotox
breast
csc
normal
breast
epitheli
cell
similarli
sayd
et
al
report
resveratrol
block
enzymat
induct
sirtuin
activ
inhibit
growth
glioma
csc
effect
normal
neural
stem
cell
fetal
brain
epigallocatechin
gallat
egcg
polyphenol
plant
camellia
sinensi
major
compon
green
tea
mani
health
benefit
includ
cancer
chemoprevent
treatment
reduct
atherosclerosi
hypercholesterolemia
alzheim
ageingrel
diseas
csc
egcg
first
studi
effect
normal
stem
cell
chen
compon
includ
egcg
inhibit
normal
rat
neurospher
adhes
migrat
egcg
pleiotrop
activ
multipl
cellular
target
genet
epigenet
includ
dna
methyltransferas
ampk
signal
pathway
act
target
impress
sensit
kd
nm
kd
laminin
receptor
cancer
egcg
target
csc
inhibit
aldh
activ
spheroid
format
express
stem
gene
oct
nanog
human
neuroblastoma
csc
similar
result
observ
breast
csc
egcg
treatment
significantli
decreas
express
nanog
number
aldh
cell
tumor
volum
mous
xenograft
furthermor
chen
et
al
report
egcg
inhibit
spheroid
format
colorect
csc
mechan
inhibit
wnt
pathway
shown
decreas
catenin
immunoblot
egcg
work
combin
phytochem
convent
drug
enhanc
anticanc
effect
target
bulk
cancer
cell
csc
synerg
quercetin
decreas
spheroid
inhibit
activ
emt
increas
apoptosi
prostat
csc
synerg
temozolomid
decreas
spheroid
pglycoprotein
synthesi
glioma
csc
found
egcg
act
synergist
cisplatin
inhibit
cisplatinresist
ovarian
cancer
cell
line
cell
cultur
vivo
egcg
cisplatin
combin
decreas
tumor
format
xenograft
head
neck
nasopharyng
csc
induc
chemosensit
cisplatin
enhanc
apoptosi
inhibit
phosphoryl
nasopharyng
csc
find
suggest
use
adjuv
cancer
therapi
genistein
isoflavon
legum
plant
glycin
max
found
soybean
classifi
phytoestrogen
bind
estrogen
receptor
genistein
activ
ingredi
soyrich
food
contribut
lower
rate
prostat
breast
cancer
china
japan
compar
western
countri
besid
anticanc
agent
genistein
health
benefit
includ
osteoporosi
heart
diseas
cognit
genistein
multipl
cellular
target
act
spectrum
protein
tyrosin
kinas
dna
topoisomeras
ii
target
csc
solid
tumor
huang
et
al
report
genistein
inhibit
spheroid
stem
oct
nanog
gene
express
reduc
xenograft
tumor
volum
gastric
csc
genistein
also
inhibit
drug
transport
extracellular
signalregul
kinas
erk
pathway
csc
breast
prostat
csc
genistein
downregul
hedgehog
pathway
reduc
gli
gene
express
decreas
spheroid
format
cell
cultur
tumor
volum
xenograft
chronic
myelogen
leukemia
cml
genistein
reduc
leukem
progenitor
cell
inhibit
express
tyrosin
kinas
code
breakpoint
cluster
regionabelson
murin
leukemia
viral
oncogen
homolog
bcrabl
fusion
gene
howev
protein
tyrosin
kinas
inhibitor
genistein
target
leukem
stem
cell
normal
stem
cell
genistein
act
synergist
convent
anticanc
agent
also
target
csc
microenviron
overcam
docetaxel
resist
decreas
tumor
size
docetaxelresist
prostat
csc
either
compound
administ
separ
breast
adipos
tissu
contribut
breast
cancer
develop
montal
et
al
found
genistein
act
csc
nich
inhibit
differenti
mammari
stromal
fibroblastlik
cell
adipocyt
mechan
inhibit
fatti
acid
synthas
gene
express
interestingli
investig
discov
genistein
biphas
effect
seen
low
dose
nm
high
dose
montal
et
al
also
found
effect
genistein
transferr
fed
mice
concentr
present
soy
protein
isol
mgkg
food
sera
could
inhibit
spheroid
format
human
breast
csc
ad
cell
cultur
suggest
presenc
csc
inhibit
factor
circul
genistein
consumpt
furthermor
genistein
transgener
effect
matern
dietari
supplement
genistein
lead
dna
hypermethyl
embryo
methyl
state
maintain
adulthood
color
chang
fur
genisteinf
agouti
mice
indic
epigenet
biosensor
nutrit
environment
alter
fetal
genom
phytochem
genistein
modifi
epigenom
effect
start
earli
embryogenesi
fdaapprov
smallmolecul
drug
diseasesdisord
shown
target
csc
process
drug
repurpos
nih
nation
center
advanc
translat
scienc
ncat
defin
repurpos
gener
refer
studi
drug
alreadi
approv
treat
one
diseas
condit
see
safe
effect
treat
diseas
rational
expedit
drug
discoveri
ncat
estim
year
new
drug
develop
therefor
strategi
reduc
time
frame
decreas
cost
improv
success
rate
mani
agent
approv
use
alreadi
test
human
detail
inform
avail
pharmacolog
formul
potenti
toxic
repurpos
build
upon
previou
research
develop
effort
new
candid
therapi
could
readi
clinic
trial
quickli
http
ncatsnihgovpreclinicalrepurpos
learnmor
drug
repurpos
also
known
drug
reposit
drug
retask
drug
reprofil
therapeut
switch
way
obtain
fast
costeffici
drug
discoveri
sinc
strategi
effect
enabl
preclin
studi
bypass
resourc
drugsurv
drug
repurpos
hub
avail
new
trick
old
drug
investig
perform
experiment
silico
vitro
vivo
search
new
target
exist
drug
csc
drug
librari
screen
assay
csc
inhibit
shown
niclosamid
thioridazin
discuss
four
csctarget
drug
metformin
niclosamid
thioridazin
chloroquin
probabl
promis
discoveri
metformin
synthet
biguanid
deriv
herb
french
lili
galega
officianali
inexpens
longapprov
drug
type
diabet
prescrib
estim
million
individu
worldwid
modul
energi
metabol
target
ampk
ampkindepend
effect
besid
diabet
metformin
shown
applic
cardiovascular
neurodegen
diseas
clinic
trial
longev
age
metformin
explor
csctarget
target
multipl
signal
pathway
wnt
ampk
metformin
use
combin
therapi
exampl
synerg
convent
combin
epirubicin
cyclophosphamid
fec
chemotherapi
inhibit
breast
csc
deriv
spheroid
enhanc
effect
denosumab
antibodi
rankl
receptor
activ
ligand
cytokin
inhibit
breast
csc
spheroid
enhanc
sensit
pancreat
csc
gemcitabin
vivo
significantli
reduc
tumor
volum
murin
xenograft
given
combin
metformin
doxorubicin
show
advantag
target
breast
csc
nonstem
cancer
cell
reduc
overal
tumor
growth
tumor
remiss
nude
mice
synergi
found
paclitaxel
carboplatin
prostat
lung
csc
murin
xenograft
phytochem
montal
et
al
report
metformin
genistein
target
colon
csc
spheroid
format
prolifer
combin
increas
effect
ning
et
al
report
curcumin
metformin
individu
inhibit
pancreat
csc
spheroid
two
compound
test
combin
exampl
suggest
combin
strategi
metformin
target
csc
cancer
next
promis
exist
drug
niclosamid
anthelminth
tapeworm
also
activ
virus
sever
acut
respiratori
syndrom
sar
viru
possibl
block
proton
carrier
niclosamid
explor
csctarget
base
gener
associ
development
stage
tapeworm
metacestod
resembl
cancer
uncontrol
prolifer
invas
metastasi
difficult
kill
without
collater
damag
surround
host
tissu
niclosamid
block
multipl
csc
signal
pathway
includ
wnt
notch
wieland
et
al
select
niclosamid
lead
glioblastoma
target
screen
member
killer
plate
compound
librari
simultan
inhibit
multipl
pathway
wnt
notch
mtor
indic
niclosamid
pretreat
inhibit
glioblastoma
xenograft
develop
nude
mice
drug
lopac
chemic
librari
yo
et
al
select
niclosamid
inhibit
breast
ovarian
csc
respect
niclosamid
inhibit
spheroid
format
reduc
tumor
volum
xenograft
nodscid
mice
act
cisplatinresist
ovarian
csc
spheroid
patientderiv
aldh
ovarian
cancer
suscept
niclosamid
inhibit
wnt
pathway
shown
catenin
immunoblot
furthermor
complement
platinum
drug
niclosamid
combin
carboplatin
inhibit
primari
ovarian
csc
combin
cisplatin
inhibit
breast
csc
spheroid
format
reduc
tumor
size
xenograft
nude
mice
thioridazin
phenothiazin
dopamin
receptor
antagonist
origin
prescrib
antipsychot
drug
schizophrenia
withdrawn
norvati
due
cardiac
side
effect
gener
version
still
avail
interest
thioridazin
recent
reviv
antimicrobi
methicillinresist
staphylococcu
aureu
mrsa
multidrugresist
mycobacterium
tuberculosi
thioridazin
target
csc
inhibit
csc
spectrum
origin
myeloid
leukemia
glioblastoma
lung
liver
ovarian
breast
cancer
inhibit
csc
spheroid
format
induc
apoptosi
vitro
treat
cell
show
reduc
xenograft
tumor
volum
mice
sachlo
et
al
select
thioridazin
screen
acut
myeloid
leukemia
aml
cscspecif
normal
pluripot
stem
cellreact
molecul
compound
nih
clinic
collect
canadian
collect
thioridazin
found
induc
aml
differenti
also
synerg
cytosin
arabinosid
cytarabin
arac
aml
csc
kill
glioblastoma
csc
induc
autophagi
seen
express
biomark
lung
hepatoma
breast
csc
induc
apoptosi
associ
activ
caspas
inhibit
stem
gene
express
inhibit
mtor
pathway
respect
synergi
convent
drug
shown
thioridazin
codeliv
doxorubicin
mix
polymer
micel
target
breast
csc
bulk
cancer
cell
found
thioridazin
curcumin
may
act
synergist
inhibit
spheroid
ovarian
cancer
cell
combin
effect
either
compound
alon
see
fig
inhibit
spheroid
thioridazin
curcumin
chloroquin
antimalari
first
discov
b
han
andersag
bayer
ignor
rediscoveri
us
armi
world
war
ii
highli
effect
well
toler
chloroquin
remain
drug
choic
malaria
accumul
within
lysosom
rais
organel
ph
inhibit
lysosom
function
malaria
parasit
chloroquin
also
use
immunosuppress
rheumatoid
arthriti
chloroquin
either
independ
combin
convent
drug
efficaci
sever
cancer
inhibit
csc
spectrum
origin
glioma
liver
pancreat
urotheli
ovarian
breast
cancer
inhibit
autophagi
spheroid
format
induc
csc
apoptosi
effect
demonstr
primari
glioma
csc
liver
csc
enrich
depriv
oxygen
nutrient
pancreat
csc
urotheli
carcinoma
csc
breast
csc
csctarget
chloroquin
show
synergist
effect
convent
therapi
sensit
radiat
chemotherapeut
agent
cancer
exampl
chloroquin
increas
cytotox
gemcitabinemitomycin
combin
urotheli
carcinoma
csc
synerg
gemcitabin
decreas
tumor
volum
pancreat
csc
xenograft
carboplatin
breast
csc
xenograft
discuss
four
phytochem
four
drug
target
csc
view
promis
novel
approach
phytochemicaldrug
combin
other
explor
csctarget
phytochem
grow
field
dietari
phytochem
includ
quercetin
flavonol
found
common
fruit
veget
appl
cranberri
onion
sulforaphan
isothiocyan
found
crucifer
broccoli
cauliflow
kale
anoth
compound
crucifer
veget
cucurbitacin
cucumb
nondietari
phytochem
includ
parthenolid
herbal
medicin
feverfew
plant
tanacetum
parthenium
celastrol
tradit
chines
medicin
thunder
god
vine
tripterygium
wilfordii
berberin
herbal
medic
plant
chines
goldthread
copti
chinensi
oxymatrin
chines
herbal
medic
plant
sophora
flavescen
silybin
silibinin
milk
thistl
silybum
marianum
gossypol
cotton
plant
genu
gossypium
similarli
list
csctarget
exist
drug
expand
repurpos
drug
includ
antiallergi
drug
tranilast
cholesterollow
statin
simvastatin
lovastatin
antialcohol
drug
disulfiram
anticip
come
challeng
start
safeti
issu
gra
statu
dietari
phytochem
appar
safe
exampl
curcumin
given
cancer
patient
mgday
month
minor
advers
effect
observ
daili
oral
dose
egcg
week
mgday
volunt
caus
minor
advers
effect
singl
oral
dose
resveratrol
g
volunt
caus
minor
advers
effect
prior
fda
approv
repurpos
drug
also
presum
safe
although
individu
compound
safe
select
synergist
csctarget
phytochemicaldrug
combin
pharmacokinet
pharmacodynam
featur
toxic
profil
still
need
inform
lack
current
clinic
trial
may
yield
use
data
see
tabl
phytochem
clinic
trial
molecular
target
phytochem
scrutini
recent
find
suggest
promiscu
multipl
target
result
perturb
cellular
membran
lead
alter
multipl
membran
protein
function
multitarget
natur
polyphenol
phytochem
hamper
therapeut
develop
high
throughput
drug
screen
assay
phytochem
includ
curcumin
resveratrol
egcg
genistein
known
panassay
interfer
compound
pain
invalid
metabol
panacea
imp
nonspecif
inhibit
wherea
may
truth
design
fact
phytochem
curcumin
caus
global
chang
gene
express
show
mere
nonspecif
protein
interact
nonetheless
multitarget
interact
specif
nonspecif
protein
nucleic
acid
level
plu
csctarget
long
normal
stem
cell
spare
addit
concern
phytochem
bioavail
vivo
product
qualiti
polyphenol
compound
effect
vivo
although
signific
less
promin
one
observ
vitro
bioavail
issu
address
enhanc
compound
piperin
spice
black
pepper
piper
nigrum
amplifi
effect
phytochem
includ
curcumin
bioavail
aid
formul
special
deliveri
system
nanoparticl
curcumin
micel
niclosamid
curcumin
exampl
manag
devis
measur
enhanc
bioavail
oral
gavag
mice
empti
stomach
demonstr
vivo
effect
curcumin
inhibit
inflammatori
ino
murin
liver
benefici
outcom
exacerb
murin
viscer
leishmaniasi
protozoan
parasit
diseas
detriment
outcom
anoth
concern
reliabl
sourc
phytochem
consist
unadulter
phytochem
essenti
exampl
curcumin
curcumin
complex
sabinsa
egcg
polyphenon
e
mitsui
norin
use
clinic
trial
see
tabl
repurpos
drug
synthet
compound
problem
yet
anoth
approach
synthesi
better
analog
deriv
difluorinatedcurcumin
variou
chloroquin
analog
beyond
scope
review
discrep
phytochem
research
result
anoth
challeng
wherea
found
curcumin
inhibit
sp
rat
glioma
found
curcumin
induc
human
glioma
csc
kakarala
et
al
report
curcumin
inhibit
breast
csc
normal
human
breast
stem
cell
thu
affect
csc
normal
stem
cell
differ
attribut
variat
dosag
length
treatment
period
grade
stabil
compound
use
experiment
condit
polyphenol
phytochem
antioxid
capac
reactiv
oxygen
speci
ro
special
condit
exhibit
prooxid
capac
wherea
ro
harm
gener
remov
much
ro
interfer
bodili
function
seen
warn
present
scientist
food
industri
relat
dosag
concept
hormesi
suggest
fundament
natur
doserespons
curv
neither
linear
threshold
uor
jshape
low
dose
stimulatori
respons
hormet
effect
repres
overcompens
respons
disrupt
homeostasi
biphas
dose
respons
observ
high
concentr
phytochem
toxic
wherea
subtox
dose
may
induc
adapt
stress
respons
hormet
mechan
action
propos
underli
mani
health
benefit
phytochem
protect
effect
resveratrol
observ
low
dose
high
dose
mous
colon
cancer
model
similar
dose
effect
seen
genistein
repurpos
drug
research
result
indic
csctarget
discord
sancho
et
al
report
metforminresist
pancreat
csc
xin
et
al
report
metforminresist
liver
csc
studi
effect
dose
metformin
much
higher
drug
phytochem
moreov
asiedu
et
al
report
heterogen
metformin
respons
patientderiv
cancer
cell
line
chloroquin
doubleedg
sword
autophagi
caus
sever
kidney
damag
whether
compound
pleiotrop
natur
lead
unexpect
advers
effect
still
unclear
repurpos
drug
studi
need
determin
reach
csc
nich
combin
treatment
long
histori
cancer
chemotherapi
first
success
exampl
treatment
childhood
leukemia
vamp
four
drug
combin
vincristin
amethopterin
prednison
approach
continu
tradit
recommend
four
phytochem
curcumin
resverestrol
egcg
genistein
four
drug
metformin
niclosamid
thioridazin
chloroquin
choic
sync
select
halifax
project
aim
multitarget
compound
cancer
prophylaxi
treatment
advoc
novel
approach
csctarget
dietari
phytochemicalrepurpos
drug
combin
look
forward
toward
clinic
applic
unit
state
cancer
drug
price
get
hand
march
report
presid
donald
trump
state
presid
cancer
panel
conclud
address
dramat
rise
cancer
drug
price
must
made
nation
prioriti
innov
drug
offer
new
hope
patient
achiev
longterm
remissionseven
curesbut
virtual
new
cancer
drug
enter
market
price
tag
exce
per
year
increasingli
much
higher
http
prescancerpanelcancergovreportdrugvalu
instead
new
cancer
drug
older
repurpos
drug
combin
dietari
phytochem
inexpens
may
work
well
cancer
worldwid
problem
affect
nation
rich
poor
topic
sullivan
et
al
warn
treat
cancer
latest
drug
techniqu
costli
improv
surviv
global
assert
cancer
rise
conclud
focu
build
infrastructur
deliv
afford
equit
effect
care
idea
csctarget
phytochemicaldrug
combin
fit
seamlessli
scenario
effect
afford
cancer
treatment
global
popul
world
health
organ
cancer
noncommunic
chronic
diseas
increas
cancer
due
age
popul
lifestyl
chang
urgent
need
afford
cancer
treatment
whether
independ
administ
combin
adjuv
current
therapi
develop
csctarget
dietari
phytochemicalrepurpos
drug
combin
afford
effect
low
toxic
goal
increas
scientif
commun
awar
build
momentum
toward
conduct
wellcontrol
clinic
trial
done
uniform
experiment
condit
doubleblind
manner
fulli
valid
novel
combinatori
approach
sinc
propos
combin
dietari
phytochem
repurpos
drug
ie
nonpatent
natur
product
patentexpir
older
drug
envis
financi
support
endeavor
come
government
philanthrop
resourc
novel
approach
readi
action
none
declar
